启明医疗-B(02500)：Cardiovalve经导管三尖瓣置换系统递交CE MDR认证申请

智通财经2025-12-24

智通财经APP讯，启明医疗-B(02500)发布公告，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。

Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593449822?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-24 07:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593449822","market":"hk","top_or_hot":-1,"title":"启明医疗-B(02500)：Cardiovalve经导管三尖瓣置换系统递交CE MDR认证申请","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02500\">启明医疗-B</a>(02500)发布公告，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。</p><p>Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>启明医疗-B(02500)：Cardiovalve经导管三尖瓣置换系统递交CE MDR认证申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n启明医疗-B(02500)：Cardiovalve经导管三尖瓣置换系统递交CE MDR认证申请\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2025-12-24 07:10</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02500\">启明医疗-B</a>(02500)发布公告，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。</p><p>Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1385227.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1385227.html","article_id":"2593449822","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593449822","pubTimestamp":1766531426,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，启明医疗-B(02500)发布公告，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK4109":"特种化学制品","BK4585":"ETF&股票定投概念","BK1583":"高瓴概念","BK1100":"医疗保健设备","02500":"启明医疗-B","BK4588":"碎股","CE":"塞拉尼斯"},"translate_title":"Qiming Medical-B (02500): Cardiovalve transcatheter tricuspid valve replacement system submits CE MDR certification application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CE":1.5,"02500":1.5},"content_text":"智通财经APP讯，启明医疗-B(02500)发布公告，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593449822","isCrawlerRequest":true}